MedTrace Logo

A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets

NCT03225352 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-06-06

No results posted yet for this study

Summary

The aim of this study is to assess disintegration of the new Aspirin disintegrating tablets

Conditions

  • Moderate Pain

Interventions

DRUG

500 mg acetylsalicylic acid (Aspirin, BAYE4465)

Single intake of 1 tablet, 500mg

DRUG

1000 mg acetylsalicylic acid (Aspirin, BAYE4465)

Single intake of 1 tablet, 1000mg

DRUG

400 mg ibuprofen(Nurofen)

Single intake of 1 tablet, 400mg

DRUG

400 mg ibuprofen (Dolormin Extra)

Single intake of 1 tablet, 400mg

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-07
Primary Completion
2017-10-07
Completion
2017-10-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03225352 on ClinicalTrials.gov